{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Paindelli C"],"funding":["Bayer HealthCare Pharmaceuticals Inc","NCI NIH HHS","University of Texas MD Anderson Cancer Center","NIH"],"pagination":["83-92"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12016311"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["178"],"pubmed_abstract":["Bone metastases are the most common milestone in the lethal progression of prostate cancer and prominent in a substantial portion of renal malignancies. Interactions between cancer and bone host cells have emerged as drivers of both disease progression and therapeutic resistance. To best understand these central host-epithelial cell interactions, biologically relevant preclinical models are required. To achieve this goal, we here established and characterized tissue-engineered bone mimetic environments (BME) capable of supporting the growth of patient-derived xenograft (PDX) cells, ex vivo and in vivo. The BME consisted of a polycaprolactone (PCL) scaffold colonized by human mesenchymal stem cells (hMSCs) differentiated into osteoblasts. PDX-derived cells were isolated from bone metastatic"],"journal":["Acta biomaterialia"],"pubmed_title":["Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo."],"pmcid":["PMC12016311"],"funding_grant_id":["P30 CA016672","P50 CA140388"],"pubmed_authors":["Barrios S","Navone N","Wang WL","Mikos AG","Pan T","Dondossola E","Shepherd P","Logothetis CJ","Campbell MT","Satcher RL","Parietti V","Paindelli C"],"additional_accession":[]},"is_claimable":false,"name":"Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo.","description":"Bone metastases are the most common milestone in the lethal progression of prostate cancer and prominent in a substantial portion of renal malignancies. Interactions between cancer and bone host cells have emerged as drivers of both disease progression and therapeutic resistance. To best understand these central host-epithelial cell interactions, biologically relevant preclinical models are required. To achieve this goal, we here established and characterized tissue-engineered bone mimetic environments (BME) capable of supporting the growth of patient-derived xenograft (PDX) cells, ex vivo and in vivo. The BME consisted of a polycaprolactone (PCL) scaffold colonized by human mesenchymal stem cells (hMSCs) differentiated into osteoblasts. PDX-derived cells were isolated from bone metastatic","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2025-07-02T03:05:04.276Z","creation":"2025-07-02T03:05:04.276Z"},"accession":"S-EPMC12016311","cross_references":{"pubmed":["38387748"],"doi":["10.1016/j.actbio.2024.02.025"]}}